Journal
BRITISH JOURNAL OF HAEMATOLOGY
Volume 195, Issue 5, Pages 757-763Publisher
WILEY
DOI: 10.1111/bjh.17865
Keywords
mantle cell lymphoma; autologous transplant; time to relapse; dynamic landmark analysis
Categories
Funding
- Public Health Service from the National Cancer Institute (NCI) [U24CA076518]
- Public Health Service from the National Heart, Lung and Blood Institute (NHLBI)
- Public Health Service from the National Institute of Allergy and Infectious Diseases (NIAID)
- Health Resources and Services Administration (HRSA) [HHSH250201700006C]
- Office of Naval Research [N00014-20-1-2705, N00014-20-1-2832]
- Be the Match Foundation
- Medical College of Wisconsin
- National Marrow Donor Program
- AbbVie
- Accenture
- Actinium Pharmaceuticals, Inc.
- Adaptive Biotechnologies Corporation
- Adienne SA
- Allovir, Inc.
- Amgen, Inc.
- Astellas Pharma US
- bluebird bio, inc.
- Bristol-Myers Squibb Co.
- CareDx
- CSL Behring
- CytoSen Therapeutics, Inc.
- Daiichi Sankyo Co., Ltd.
- Eurofins Viracor
- ExcellThera
- Fate Therapeutics
- Gamida Cell, Ltd.
- Genentech Inc
- Gilead
- GlaxoSmithKline
- Incyte Corporation
- Janssen/Johnson Johnson
- Jasper Therapeutics
- Jazz Pharmaceuticals, Inc.
- Karyopharm Therapeutics
- Kiadis Pharma
- Kite, a Gilead Company
- Kyowa Kirin
- Magenta Therapeutics
- Medac GmbH
- Merck Co.
- Millennium, the Takeda Oncology Co.
- Miltenyi Biotec, Inc.
- MorphoSys
- Novartis Pharmaceuticals Corporation
- Omeros Corporation
- Oncopeptides, Inc.
- Orca Biosystems, Inc.
- Pfizer, Inc.
- Pharmacyclics, LLC
- Sanofi Genzyme
- Seagen, Inc.
- Stemcyte
- Takeda Pharmaceuticals
- Tscan
- Vertex
- Vor Biopharma
- Xenikos BV
Ask authors/readers for more resources
In young and fit patients with mantle cell lymphoma, intensive induction therapy followed by autologous haematopoietic cell transplant is the standard care. Time to relapse after autoHCT has a significant impact on overall survival, with early relapse defining a high-risk group with inferior post-relapse survival. This study highlights the importance of considering novel therapeutic approaches for MCL patients suffering early relapse after upfront autoHCT.
In young and fit patients with mantle cell lymphoma (MCL), intensive induction therapy followed by a consolidative autologous haematopoietic cell transplant (autoHCT) is the standard of care in the front-line setting. Recently, time-to-event analysis has emerged as an important risk assessment tool in lymphoma, though its impact in MCL is not well defined. We utilized the Center for International Blood and Marrow Transplant Research database to evaluate the effect of post-autoHCT time to relapse on overall survival (OS) over time in 461 patients who underwent autoHCT within 12 months of MCL diagnosis. On multivariate analysis, the impact of relapse on OS was greatest at the six-month [hazard ratio (HR) = 7 center dot 68], 12-month (HR = 6 center dot 68), and 18-month (HR = 5 center dot 81) landmark timepoints. Using a dynamic landmark model we demonstrate that adjusted OS at five years following each landmark timepoint improved with time for relapsing and non-relapsing patients. Furthermore, early relapse (<18 months) following autoHCT defines a high-risk group with inferior post-relapse OS. This retrospective analysis highlights the impact of time to relapse on OS in MCL patients undergoing up-front autoHCT and emphasizes the need to consider novel therapeutic approaches for patients suffering early relapse.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available